United Kingdom Colorectal Cancer Therapeutics Market to be Dominated by Immunotherapy Segment through 2028
Increasing prevalence of colorectal cancer and
changing lifestyle are expected to drive the United Kingdom Colorectal Cancer Therapeutics
Market in the forecast period, 2024-2028.
According to TechSci Research report, “United Kingdom Colorectal Cancer Therapeutics Market –
By Region, Competition Forecast and Opportunities, 2018-2028,” the United
Kingdom Colorectal Cancer Therapeutics Market is projected to experience
significant growth during the forecast period, 2024-2028. In the last decade,
there has been a noticeable increase in public awareness campaigns aimed at
promoting colorectal cancer screening and early detection. These initiatives
have effectively educated the general population about the importance of
regular screenings, such as colonoscopies, fecal occult blood tests, and
sigmoidoscopies. Early detection of the disease leads to improved treatment
outcomes and higher survival rates. Furthermore, advancements in diagnostic
techniques have enhanced the accuracy and effectiveness of colorectal cancer
screening. Non-invasive tests, like DNA-based stool tests, have gained popularity
due to their convenience and ability to detect genetic mutations associated
with colorectal cancer. Medical imaging technologies, such as computed
tomography (CT) scans and magnetic resonance imaging (MRI), have also improved
the ability to detect and stage colorectal cancer. The growing geriatric
population in the United Kingdom is a key driver for the expansion of the
colorectal cancer therapeutics market. The increasing prevalence of colorectal
cancer among the elderly necessitates the development of innovative treatment
options tailored to their specific needs. Another significant risk factor for
colorectal cancer is obesity, which is linked to a sedentary lifestyle.
Surprisingly, this elevated risk is associated with increased calorie intake as
well as visceral adipose tissue, a hormonally active subset of total body fat
that can promote the growth of colorectal cancer through the secretion of
proinflammatory cytokines, leading to inflammation in the colon and rectum,
insulin resistance, and the modulation of metabolic enzymes like adiponectin or
lectin. The rising prevalence of colorectal cancer has directly impacted the
Colorectal Cancer Therapeutics Market in the United Kingdom. The demand for
effective treatment options, coupled with advancements in precision medicine
and immunotherapies, has driven the growth of this market. With advancements in
surgical techniques, chemotherapy, targeted therapy, and immunotherapy, the
healthcare industry is better equipped to address the challenges posed by this disease,
thereby propelling the growth of the United Kingdom Colorectal Cancer
Therapeutics Market during the projected period. However, challenges such as
the high cost of innovative therapies, limited access to certain treatments,
lack of skilled healthcare professionals, high expenses associated with
personalized treatment regimens, treatment resistance, adverse effects, and
disparities in healthcare provision may hinder the market's growth in the
forecast period.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on “United Kingdom Colorectal Cancer Therapeutics Market “
The United Kingdom Colorectal Cancer Therapeutics
Market is categorized by Drug Class, End User, and Region and Competitive
Landscape.
Regarding Drug Class, the market is segmented into
Chemotherapy, Immunotherapy, and Others. The immunotherapy segment is expected
to experience growth during the forecast period. This is attributed to the
favorable outcomes observed in patients with tumors that exhibit microsatellite
instability or mutations impairing mismatch repair. The results of immunotherapy
for colorectal cancer have been remarkable, which is anticipated to foster
market expansion in the future.
Concerning End User, the market is divided into
Hospitals, Clinics, and Others. The hospital segment is projected to witness
growth in the forecast period. This can be attributed to the availability of
advanced technologies, skilled healthcare staff, and comprehensive inpatient
and outpatient medical facilities. These factors are expected to contribute to
the market's growth in the future.
Major
companies operating in the United Kingdom Colorectal Cancer Therapeutics Market
are:
- Novartis AG
- Pfizer Inc
- Eli Lilly & Company
- Merck Co. & Inc.
- GlaxoSmithKline, Plc.
- AstraZeneca Plc
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Sanofi S.A.
- Roche Holding AG
Download Free Sample Report
Customers can also request
10% free customization in this report.
“The United Kingdom Colorectal Cancer Therapeutics
Market is anticipated to experience significant growth in the upcoming years.
This can be attributed to the increasing prevalence of colorectal cancer,
combined with the growing awareness among the population regarding the causes,
symptoms, and treatment of colorectal cancer within the country. Moreover, the
market is witnessing substantial growth driven by the rising geriatric
population and the subsequent demand for effective treatment options.
Additionally, advancements in oncological technology have contributed to the
increased demand for colorectal cancer therapeutics, which is expected to continue
to grow through 2028.” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based global management consulting firm.
“United Kingdom Colorectal Cancer Therapeutics
Market By Drug Class (Chemotherapy, Immunotherapy, Others), By End User
(Hospitals, Clinics, Others), By Region, Competition Forecast &
Opportunities, 2018-2028F,” has evaluated the future growth potential of United
Kingdom Colorectal Cancer Therapeutics Market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in United Kingdom Colorectal Cancer Therapeutics Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]
Website:
www.techsciresearch.com